The latest biotech news

mutabilis novo holdings antibiotic resistance

News and Trends 6 Jan 2020

€5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic

Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jan 2020

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […]

January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2019

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals. The fundraising was co-led by food tech investor Agronomics and M Ventures, the corporate venture capital arm of Merck. CPT Capital, an investor in alternative proteins, […]

December 20, 2019 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Dec 2019

CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA

The German biotech CureVac has signed a deal potentially worth over €1B with Danish antibody developer Genmab to develop messenger RNA drugs that carry the instructions for therapeutic antibodies to be produced inside cancer patients. “We believe that the collaboration with Genmab represents the first antibody deal in the field of mRNA,” stated Daniel Menichella, […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2019

Update: First Ever Ebola Vaccine Gets US and EU Approval

Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval for its Ebola vaccine, the first to be approved in both regions. Published on 13/11/2019 The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2019

Freeline’s Rare Disease Gene Therapies Get €72M Series C Boost

The UK gene therapy biotech Freeline Therapeutics is to receive an investment worth €72M (£61.1M) from the UK VC firm Syncona in a Series C round to fund the clinical development of gene therapies for the blood disorder hemophilia B, Fabry disease, and other rare conditions. Of the €72M commitment, Syncona has already wired €36M […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 18 Dec 2019

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers that have a mutation in the Notch pathway, a group of proteins that helps cells communicate with each other. Many cancers have mutations in these […]

December 18, 2019 - 2 minutesmins - By Helen Albert

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

December 17, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 16 Dec 2019

Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease

A treatment developed by the Irish company Amarin has become the first FDA-approved drug to lower the risk of strokes and heart attacks when combined with statins in patients with high levels of circulating fat molecules called triglycerides. To be eligible for Vascepa, patients must also either have established cardiovascular disease, or type 2 diabetes […]

December 16, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Dec 2019

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

French biotech Transgene has ceased the development of a therapeutic cancer vaccine that failed to shrink tumors in patients with lung cancer in a phase II trial. In the phase II trial, Transgene tested its therapeutic cancer vaccine in combination with chemotherapy and the checkpoint inhibitor drug nivolumab, marketed as Opdivo. The treatment failed to […]

December 13, 2019 - 2 minutesmins - By Jonathan Smith

antibiotic resistance iterum therapeutics

News and Trends 12 Dec 2019

Iterum Therapeutics Reels from Antibiotic Phase III Fail

An antibiotic candidate developed by the Irish company Iterum Therapeutics has failed to meet the main goal of a phase III trial, a blow for efforts to meet the challenge of global antibiotic resistance. Iterum Therapeutics’ drug sulopenem was tested in a phase III trial that recruited 674 patients suffering from complicated intra-abdominal infections. These […]

December 12, 2019 - 2 minutesmins - By Jonathan Smith

cancer immunotherapy immunos therapeutics

News and Trends 11 Dec 2019

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

The Swiss biotech ImmunOs Therapeutics has raised a Series A round of €13.7M (CHF 15M) that will fund the first human trials of its cancer immunotherapy that could improve the response of cancer patients to checkpoint inhibitors. The round was co-led by the Swiss life sciences venture capital firm BioMedPartners and by Pfizer Ventures. The […]

December 11, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

€5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA

Update: First Ever Ebola Vaccine Gets US and EU Approval

Freeline’s Rare Disease Gene Therapies Get €72M Series C Boost

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease

Transgene’s Cancer Vaccine Abandoned after Phase II Fail

Iterum Therapeutics Reels from Antibiotic Phase III Fail

€14M Series A to Fund Cancer Immunotherapy Boosting Checkpoint Inhibitors

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!